Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACT-Pros: Treatment for Residual Cervical Adenocarcinoma
NCT07153952Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, DNA Intercalators/Alkylators, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neratinib, alpelisib, carboplatin, paclitaxel and cisplatin in cervical adenocarcinoma and cervical adenosquamous carcinoma (ASC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Tumor control rate at 3 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
neratinibalpelisibcarboplatinpaclitaxelcisplatin
03
Conditions
cervical adenocarcinomacervical adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on NCT07153952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153952.